Business Wire

TX-ABB

Share
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future

ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas – showcasing a number of concept technologies, including a mobile YuMi® robot, which will be designed to assist medical and laboratory staff with laboratory and logistics tasks in hospitals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005527/en/

The dual-arm mobile YuMi® will be able to sense and navigate its way around its human co-workers autonomously, while learning to find different routes from one location to another. It has the potential to undertake a wide range of repetitive and time-consuming activities, including preparation of medicines, loading and unloading centrifuges, pipetting and handling liquids and picking up and sorting test tubes.

The mobile YuMi®could also be used in hospitals for a wide variety of logistics roles. YuMi® may be able to dispense medicines, transport them to where they are needed in hospitals, bring medical supplies to hospital staff and bed linen direct to patients’ bedrooms.

At TMC Innovation Institute, ABB will develop robots that are able to carry out repetitive, delicate and mundane processes, leaving highly skilled medical and laboratory staff free to undertake more valuable roles and ultimately treat more patients. ABB analysis shows that repetitive tasks could be completed up to 50 per cent faster with automation, compared to current manual processes, with the added benefit that robots can work 24 hours a day.

“The healthcare sector is undergoing significant transformation as the diagnosis and treatment of disease advances, while coping with an aging population, increasing costs and a growing worldwide shortage of medical staff. With our new healthcare research and development hub at TMC we are aiming to develop answers to these challenges – together with the best minds in academia, science and medicine,” said Sami Atiya, President of ABB’s Robotics and Discrete Automation business. “Our experience in industrial and collaborative robotics will give us a strong basis to be able to adapt flexible automation to the healthcare sector. Together with our partners at TMC, we will develop cutting-edge robotics solutions. We are working to reduce the number of manual procedures performed by medical staff, improve the accuracy of laboratory work and enhance patient satisfaction and ultimately patient safety.”

Other technologies showcased by ABB at the Healthcare Research Hub include YuMi® robots that could aid in centrifuge tending and test tube handling systems, and an IRB 1200 robot that could execute liquid transfers in a pipetting application. All are common medical laboratory tasks that robotic automation may be able to support by combining consistent performance with a level of flexibility and continuous operation that could increase throughput and quality while minimizing costs.

TMC is the largest medical city in the world with world-class collaborative research resources, including some of the world’s leading companies and hospitals. ABB’s new 5,300 sq ft (500m2 ) Healthcare Hub will be housed at the TMC Innovation Institute, a state-of-the-art hub that fosters collaboration of medicine and cutting-edge technology, connecting start-ups with pioneers in academia and leading technology companies in order to accelerate the development and prototyping of breakthrough medical technology.

“Texas Medical Center, TMC Innovation, and the entire TMC network of member institutions are pleased to welcome ABB on the occasion of its first foray into the healthcare space with this incredible and unprecedented new robotics facility,” emphasized Bill McKeon, President & CEO of Texas Medical Center. He added, “A primary goal across TMC – the largest medical city in the world – is to make research happen faster while simultaneously cutting costs in order to create more rapid and cost-effective solutions for patients who are in desperate need of treatment. ABB’s move into the heart of the Texas Medical Center campus with this first-of-its-kind R&D facility for creating robotics solutions in healthcare will set a new course for advancements in medicine and establish TMC as the nexus for a new kind of synergistic partnership that will shape the future of healthcare for clinicians, researchers, and patients alike.”

Robotic automation in the healthcare sector offers significant opportunity for future growth. According to internal ABB research, the global market is estimated to reach nearly 60,000 non-surgical medical robots by 2025, a fourfold increase from 2018.

Watch the video: https://youtu.be/SA_1vfH5UIk

Media b-roll: https://drive.google.com/file/d/13r9gjaXpLCZmJ69m6m6YyVDM9ONkauQO/view

ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

TMC INNOVATION

Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral8.7.2025 10:00:00 CEST | Press release

Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/ Sopral products The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed. Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, th

Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release

At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release

Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime

Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release

Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha

Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye